Treatment of Schizophrenia with Aripiprazole. A one year open-label study.

Phase 4

Recruiting

• Conditions: Schizophrenia; Mental Health - Schizophrenia

• Registration Number: ACTRN12605000394640
• Lead Sponsor: Associate Professor Krishna Vaddadi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-14
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients who are outpatients (private or public) attending southern health facility and have a well established diagnosis of schizophrenia (DSM-IV diagnosis criteria), who report side effects on their existing medication, who have not fully responded to their current therapy, who in the clinicians opinion, would benefit from Aripiprazole, who are able to comprehend what is happening to them and able to give informed consent, who can speak a reasonable level of English, and where completing rating scales with adequate information is not a practical problem.

Exclusion Criteria

Patients who want to become pregnant during the study period, with alcohol dependence, with acquired brain injury associated with schizophrenia, who are on too complex medication regimes which would be difficult to change, who have previously been treated with Aripiprazole, who are on very high doses of clozapine in (>500mg/day), on very high doses of injectable Zuclopenthixol Decanoate (>200mg/fortnight), with a past history of severe violence/suicidal risk, who are generally non-compliant with oral medication, who have poor social supports and are very unreliable with appointments, and patients who are very stable on their current antipsychotic medication, but want to change to Aripiprazole simply because it is a new drug, their friend got better or, someone told them it is a good idea.

Study & Design

• Study Type: Interventional
• Study Design: Not specified